Frontiers in Pediatrics | |
Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic | |
Sara Della Paolera1  Alberto Tommasini2  Andrea Taddio2  Manola Comar2  Raffaella Sagredini3  Erica Valencic3  Valentina Moressa3  Valentina Kiren3  Elisa Piscianz3  | |
[1] Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy;Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy;Institute of Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy;Institute of Maternal and Child Health IRCCS “Burlo Garofolo”, Trieste, Italy; | |
关键词: MISC-C; PIMS-TS; COVID-19; SARS-CoV-2; Kawasaki; anakinra; IL-1; | |
DOI : 10.3389/fped.2020.624248 | |
来源: Frontiers | |
【 摘 要 】
During COVID-19 outbreak, a large number of children with severe inflammatory disease has been reported. This condition, named Pediatric Multi-inflammatory Syndrome temporally associated with COVID-19 (PIMS-TS) or Multisystem Inflammatory Syndrome associated with Coronavirus Disease 2019 (MIS-C), shares some clinical features with Kawasaki disease and is frequently complicated by myocarditis or shock. It has been suggested that MIS-C belongs to the group of cytokine storm syndromes triggered by SARS-CoV-2 infection. So far, intravenous immunoglobulin (IVIG) and systemic glucocorticoids are the most common therapeutic approaches reported in this group of patients. However, the use of anakinra in patients with severe forms of COVID-19 is showing promising results. Here we reported two patients with multisystem inflammatory syndrome complicated with shock. Both the patients presented a poor response to IVIG and systemic glucocorticoids and received anakinra. Treatment with IL-1 receptor antagonist showed a rapid improvement of clinical conditions and biochemical analysis in both patients and demonstrated a good safety profile. Thus, we look forward for future controlled clinical trials with the aim to demonstrate the effectiveness of anakinra in patients with MIS-C and established precise criteria for its use.
【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202107162239740ZK.pdf | 518KB | download |